Critical Comparison: GW Pharmaceuticals PLC- (GWPH) & Halozyme Therapeutics (HALO)
GW Pharmaceuticals PLC- (NASDAQ: GWPH) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.
This is a summary of current recommendations and price targets for GW Pharmaceuticals PLC- and Halozyme Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|GW Pharmaceuticals PLC-||0||1||7||0||2.88|
Volatility & Risk
GW Pharmaceuticals PLC- has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500.
Insider & Institutional Ownership
81.9% of GW Pharmaceuticals PLC- shares are held by institutional investors. Comparatively, 84.5% of Halozyme Therapeutics shares are held by institutional investors. 5.5% of GW Pharmaceuticals PLC- shares are held by company insiders. Comparatively, 16.8% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares GW Pharmaceuticals PLC- and Halozyme Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|GW Pharmaceuticals PLC-||-1,607.85%||-40.42%||-34.97%|
Earnings & Valuation
This table compares GW Pharmaceuticals PLC- and Halozyme Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|GW Pharmaceuticals PLC-||$11.00 million||328.72||-$166.90 million||($6.72)||-19.38|
|Halozyme Therapeutics||$146.69 million||19.11||-$103.02 million||($0.68)||-28.96|
Halozyme Therapeutics has higher revenue and earnings than GW Pharmaceuticals PLC-. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than GW Pharmaceuticals PLC-, indicating that it is currently the more affordable of the two stocks.
Halozyme Therapeutics beats GW Pharmaceuticals PLC- on 7 of the 13 factors compared between the two stocks.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company’s commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant. The Company’s development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.